Dr. Dayem joins Amgen from Merck & Co. where he was vice president, information services and chief information officer for worldwide computer and telecommunications technology. At Merck, Dr. Dayem moved the company to manage its computations infrastructure on a global scale. At Amgen, Dr. Dayem will direct 500 information technology professionals in the U.S. and Europe.
"Dr. Dayem is an internationally recognized information technologies expert who will make information systems a sustainable, competitive advantage for Amgen as we pursue our aggressive growth plans," said Kevin Sharer, Amgen's CEO.
Before joining Merck in 1997, Dr. Dayem was division director for the computing, information, and communications division of the Los Alamos National Laboratory, which he joined in 1977. At Los Alamos, Dr. Dayem was a key architect in developing the nation's next-generation high-performance computing capability.
Dr. Dayem holds a Ph.D. in Nuclear Engineering from the University of Maryland.
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent Form 10-Q. Amgen conducts research in the biotechnology/pharmaceutical field where movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.
Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. In addition, sales of our products are affected by reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers. These government regulations and reimbursement policies may affect the development, usage and pricing of our products.
In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.
Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Amgen. Amgen is providing this information as of May 10, 2002 and expressly disclaims any duty to update information contained in this press release.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on advances
in cellular and molecular biology.
# # #
Contact: Amgen, Thousand Oaks
Jeff Richardson, 805/447-3227 (media)
Cary Rosansky, 805/447-4634 (investors)